A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-Intermediate Risk Diffuse Large B-Cell Lymphoma.

Trial Profile

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-Intermediate Risk Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Aug 2014 Planned End Date changed from 1 Jan 2016 to 1 Jul 2015 as reported by ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top